Epidiolex, a newly approved treatment for epileptic seizures that contains highly purified cannabidiol (CBD), has been placed in Schedule V of the Controlled Substances Act. The U.S. Food and Drug Administration approved Epidiolex for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years o... Read More